Women using the dapivirine vaginal ring (an HIV prevention method) reported more sex with nonprimary partners compared to placebo, but condom use remained stable. This suggests modest behavioral risk compensation without complete abandonment of safer sex practices.
The dapivirine vaginal ring is a long-acting HIV prevention tool designed for women who want discreet, user-controlled protection. But introducing any new prevention technology raises a critical question: do people who feel protected change their sexual behavior in ways that offset the protection's benefits? This is called risk compensation, and researchers needed to measure whether it occurred in real-world use.
This analysis tracked sexual behavior in two linked studies. The first, ASPIRE (MTN-020), was a randomized placebo-controlled trial in Malawi, South Africa, Uganda, and Zimbabwe. Of 2,629 women enrolled in ASPIRE, 1,456 (55%) continued into HOPE (MTN-025), an open-label extension where all participants knew they were receiving the dapivirine ring. The key comparison: did behavior change when women transitioned from blinded placebo to known active prevention?
The findings reveal a nuanced picture. At enrollment into both studies, sexual behavior looked identical. But over 12 months of follow-up, a clear pattern emerged. Women in HOPE reported sex with nonprimary partners in 13.9-18.7% of quarterly visits, compared to 10.7-12.6% in ASPIRE. This difference was statistically significant (adjusted odds ratio 1.47, 95% CI 1.24-1.75). Translated to actual risk: roughly 4-6 additional percentage points of women reporting nonprimary sexual contact when they knew they had active protection versus placebo.
However, the critical safety metric—condom use—showed no meaningful change. In ASPIRE, 36.5-42.7% of participants reported condom use at their last vaginal sex act. In HOPE, this was 43.6-46.7%. The difference was not statistically significant (adjusted OR 1.05, 95% CI 0.94-1.18). This suggests that while more women pursued sex with additional partners when protected by the ring, they did not systematically abandon condoms. The study authors note this finding "allows for tailored, holistic reproductive health programming"—meaning prevention strategies can account for actual behavioral patterns rather than worst-case scenarios.
One critical limitation: the comparison is not perfect. Only 55% of ASPIRE participants enrolled in HOPE, and those who continued may differ from those who dropped out. Women who chose to continue knew they were receiving active medication, which itself could influence behavior independent of how protected they actually felt. The analysis cannot definitively separate the effect of having real protection versus knowing you have real protection.
If you're evaluating any new health intervention—whether a prevention method, supplement, or screening tool—this study illustrates why real-world behavior matters. Theoretical protection only works if people use it as intended. The dapivirine ring's modest increase in sexual contact with nonprimary partners didn't produce a public health disaster because women maintained reasonable condom use patterns.
For HIV prevention specifically: long-acting methods like the vaginal ring reduce but don't eliminate the need for other precautions. A slight increase in sexual contact isn't surprising when protection feels more reliable and requires less active decision-making than condoms. This pattern has been observed with other prevention tools. The key insight is that women didn't replace all safer sex practices with the ring alone—they used it alongside existing (though imperfect) condom use.
For health researchers and public health programs: assuming worst-case behavioral responses often leads to overly restrictive rollout strategies. This data suggests more nuanced messaging is possible: "This tool works alongside your existing practices, and real people use it that way."
| Parameter | Details |
|---|---|
| Study Type | Randomized controlled trial with open-label extension |
| Sample Size | 2,629 in ASPIRE; 1,456 in HOPE |
| Duration | 12 months follow-up in each study; quarterly behavioral assessments |
| Population | Healthy, sexually active, HIV-negative women aged 18-45 from Malawi, South Africa, Uganda, Zimbabwe |
| Intervention | Dapivirine vaginal ring (HOPE); placebo ring (ASPIRE) |
| Primary Outcomes | Sex with nonprimary partner (past 3 months); condom use at last vaginal sex |
| Main Findings | Increased nonprimary partner contact in HOPE (OR 1.47); no difference in condom use (OR 1.05, NS) |
| Registered | ClinicalTrials.gov |
National Center for Biotechnology Information. "Changes in sexual behavior among women in studies evaluating the dapivirine vaginal ring for HIV prevention." *Sexual Health*. PubMed: 42618053
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.